Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BWAY NASDAQ:CODX OTCMKTS:EDTXF NASDAQ:PAVM NASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWAYBrainsway$12.64-2.8%$10.92$5.98▼$13.66$238.83M1.467,737 shs20,594 shsCODXCo-Diagnostics$0.25-10.6%$0.29$0.23▼$2.23$8.46M0.6303,481 shs12.16 million shsEDTXFSpectral Diagnostics$0.62-0.2%$0.61$0.32▼$0.65$176.79M0.2214,848 shs4,900 shsPAVMPAVmed$0.60+0.2%$0.65$0.54▼$1.90$10.25M1.06137,063 shs113,531 shsXAIRBeyond Air$0.20-7.1%$0.19$0.15▼$0.68$16.84M0.221.56 million shs2.60 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWAYBrainsway+1.01%+1.56%+18.07%+54.21%+111.73%CODXCo-Diagnostics+0.54%-1.50%-5.50%-16.36%-77.10%EDTXFSpectral Diagnostics+3.40%+2.85%+2.56%+26.61%+79.98%PAVMPAVmed+8.01%+1.30%-6.77%-11.96%-23.24%XAIRBeyond Air+0.96%+18.11%+11.35%-8.70%-62.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBWAYBrainsway2.2151 of 5 stars2.53.00.00.00.00.81.9CODXCo-Diagnostics3.7118 of 5 stars3.55.00.04.40.00.01.3EDTXFSpectral Diagnostics0.2419 of 5 stars0.05.00.00.00.00.00.0PAVMPAVmed4.3659 of 5 stars3.55.00.04.30.00.01.9XAIRBeyond Air3.9037 of 5 stars3.73.00.03.51.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBWAYBrainsway 3.00Buy$14.2512.74% UpsideCODXCo-Diagnostics 3.00Buy$5.502,083.41% UpsideEDTXFSpectral Diagnostics 0.00N/AN/AN/APAVMPAVmed 3.00Buy$19.003,066.67% UpsideXAIRBeyond Air 3.33Buy$1.50669.23% UpsideCurrent Analyst Ratings BreakdownLatest CODX, EDTXF, XAIR, BWAY, and PAVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025BWAYBrainswayHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/6/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.50 ➝ $19.004/28/2025CODXCo-DiagnosticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025CODXCo-DiagnosticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/21/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $19.50(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBWAYBrainsway$43.46M5.50$0.24 per share51.61$3.31 per share3.82CODXCo-Diagnostics$3.71M2.28N/AN/A$1.70 per share0.15EDTXFSpectral Diagnostics$1.67M105.86N/AN/A($0.07) per share-8.85PAVMPAVmed$2.99M3.43N/AN/A($0.92) per share-0.65XAIRBeyond Air$3.71M4.55N/AN/A$0.17 per share1.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBWAYBrainsway$2.92M$0.2063.2079.00N/A9.01%7.35%4.72%8/5/2025 (Estimated)CODXCo-Diagnostics-$37.64M-$1.17N/AN/AN/A-1,025.45%-60.16%-52.69%8/6/2025 (Estimated)EDTXFSpectral Diagnostics-$11.24M-$0.07N/A∞N/A-1,078.10%N/A-336.97%8/7/2025 (Estimated)PAVMPAVmed$39.79M$0.710.85N/AN/A3,711.54%N/A-42.29%8/12/2025 (Estimated)XAIRBeyond Air-$46.62M-$0.79N/AN/AN/A-1,258.46%-233.96%-113.92%8/5/2025 (Estimated)Latest CODX, EDTXF, XAIR, BWAY, and PAVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025BWAYBrainsway$0.07N/AN/AN/A$12.34 millionN/A8/5/2025Q1 2026XAIRBeyond Air-$0.08N/AN/AN/A$1.75 millionN/A6/17/2025Q4 2025XAIRBeyond Air-$0.14-$0.09+$0.05-$0.09$1.39 million$1.15 million5/13/2025Q1 2025BWAYBrainsway$0.02$0.04+$0.02$0.04$11.45 million$11.54 million5/9/2025Q1 2025EDTXFSpectral DiagnosticsN/A-$0.03N/A-$0.03N/A$0.40 million5/8/2025Q1 2025CODXCo-Diagnostics-$0.33-$0.24+$0.09-$0.24$0.38 million$0.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBWAYBrainswayN/AN/AN/AN/AN/ACODXCo-DiagnosticsN/AN/AN/AN/AN/AEDTXFSpectral DiagnosticsN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBWAYBrainswayN/A5.034.75CODXCo-DiagnosticsN/A4.434.23EDTXFSpectral DiagnosticsN/A0.090.08PAVMPAVmedN/A0.370.37XAIRBeyond Air0.643.202.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBWAYBrainsway30.11%CODXCo-Diagnostics14.99%EDTXFSpectral DiagnosticsN/APAVMPAVmed19.93%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipBWAYBrainsway19.00%CODXCo-Diagnostics8.40%EDTXFSpectral Diagnostics1.50%PAVMPAVmed7.30%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBWAYBrainsway12018.90 million15.31 millionNot OptionableCODXCo-Diagnostics10033.57 million30.75 millionOptionableEDTXFSpectral Diagnostics29285.52 million281.24 millionNot OptionablePAVMPAVmed9017.09 million15.85 millionOptionableXAIRBeyond Air7086.37 million69.61 millionOptionableCODX, EDTXF, XAIR, BWAY, and PAVM HeadlinesRecent News About These CompaniesBeyond Air Implements Reverse Stock Split for Nasdaq ComplianceJuly 10 at 8:44 AM | tipranks.comBeyond Air Inc.June 26, 2025 | barrons.comHere's Why Beyond Air (XAIR) Could be Great Choice for a Bottom FisherJune 26, 2025 | zacks.comBeyond Air (XAIR) Q4 2025 Earnings Call TranscriptJune 21, 2025 | msn.comBeyond Air, Inc. (NASDAQ:XAIR) Q4 2025 Earnings Call TranscriptJune 20, 2025 | msn.comBeyond Air posts narrower-than-feared Q4 loss, shares surge 15%June 18, 2025 | investing.comBeyond Air Reports Strong Revenue Growth and Strategic AdvancesJune 17, 2025 | tipranks.comBeyond Air, Inc. (XAIR) Q4 2025 Earnings Call TranscriptJune 17, 2025 | seekingalpha.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | finance.yahoo.comBeyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue EstimatesJune 17, 2025 | zacks.comBeyond Air Stock Dips After Mixed Q4 Results: Here's What To KnowJune 17, 2025 | benzinga.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | globenewswire.comBeyond Air Submits PMA Supplement Application for Next-Generation LungFit PH II Nitric Oxide GeneratorJune 16, 2025 | quiverquant.comQBeyond Air Submits FDA PMA Supplement for Next Generation LungFit® PHJune 16, 2025 | globenewswire.comBeyond Oil Issues Clarification Regarding Previous German-Language Media ActivitiesJune 3, 2025 | globenewswire.comBeyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and WebcastMay 20, 2025 | globenewswire.comBeyond Air granted U.S. patent for gaseous nitric oxide deliveryApril 25, 2025 | markets.businessinsider.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Gets Patent for Lung Infection TreatmentApril 25, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCODX, EDTXF, XAIR, BWAY, and PAVM Company DescriptionsBrainsway NASDAQ:BWAY$12.64 -0.36 (-2.77%) Closing price 04:00 PM EasternExtended Trading$12.64 0.00 (0.00%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Co-Diagnostics NASDAQ:CODX$0.25 -0.03 (-10.58%) Closing price 04:00 PM EasternExtended Trading$0.25 +0.00 (+0.83%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Spectral Diagnostics OTCMKTS:EDTXF$0.62 0.00 (-0.19%) As of 11:31 AM EasternSpectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.PAVmed NASDAQ:PAVM$0.60 +0.00 (+0.22%) Closing price 04:00 PM EasternExtended Trading$0.59 -0.01 (-1.17%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Beyond Air NASDAQ:XAIR$0.20 -0.02 (-7.14%) Closing price 04:00 PM EasternExtended Trading$0.19 0.00 (-1.03%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
